04:30
Gene Therapy Explained
02:26
Foundation Park: a Home for Life Science Innovation in North Central Florida
02:10
Sheep with Achromatopsia Are Able to Navigate a Maze After Gene Therapy
03:34
About the University of Florida Office of Technology Licensing
01:54
Michigan State University, UPenn and AGTC’s Gene Therapy Proof-of-Concept for Achromatopsia
12:54
AGTC CEO Sue Washer's Presentation at the ARM's 3rd Annual Regen Med Investor Day
02:53
AGTC’s Technology
04:40
AGTC speaks with OIS Co-Chair Gil Kliman at the OIS@AAO Innovator Award Presentation
03:06
AGTC’s Sue Washer on Ophthalmology IPOs
02:39
AGTC’s Sue Washer featured on The Corridor Magazine’s Faces of Technology
00:45
AGTC Technology’s Effect on Canines
02:21
AGTC Company Overview
03:06
AGTC: A Great Place To Work
X
About
AGTC is developing treatments for rare lung and eye diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, we use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. We use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.
The innovative delivery method AGTC uses is the non-toxic adeno-associated virus (AAV), a safe virus that delivers healthy copies of the gene, replacing defective copies.
Tags